Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.02 - Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
15:55 - 16:05 | Presenter: Jhanelle Elaine Gray | Author(s): Isamu Okamoto, V. Sriuranpong, Johan F. Vansteenkiste, F. Imamura, J.S. Lee, Y. Pang, M. Cobo, K. Kasahara, R. Hodge, Brian B Lentrichia, S. Dearden, Suresh S Ramalingam
- Abstract
Loading...
-
+
MS 17 - Lessons Learned from Negative Trials
- 15:45 - 17:30
- 10/17/2017
- Location: Room 303 + 304
- Type: Mini Symposium
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:V. Sriuranpong, Johan F. Vansteenkiste
-
+
MS 17.01 - PROCLAIM
15:45 - 15:55 | Presenter: Anthony Brade
- Abstract
No abstract available for this presentation
-
+
MS 17.02 - MAGRIT
15:55 - 16:05 | Presenter: Johan F. Vansteenkiste
- Abstract
Loading... -
+
MS 17.03 - Is There Such a Thing as a ‘Negative’ Trial?
16:05 - 16:30 | Presenter: Lucinda Jane Billingham
- Abstract
Loading... -
+
MS 17.04 - MET-Lung: A Phase III Trial of Onartuzumab (METMab) Plus Erlotinib vs Erlotinib in Previously Treated Stage IIIB or IV NSCLC
16:30 - 16:40 | Presenter: Karen Kelly
- Abstract
Loading... -
+
MS 17.05 - CheckMate026
16:40 - 16:50 | Presenter: David P Carbone
- Abstract
No abstract available for this presentation
-
+
MS 17.06 - Avoiding Phase II-III Attrition: Enhanced Biomarkers, Better Drugs or Improved Trial Design?
16:50 - 17:15 | Presenter: John Crowley
- Abstract
Loading... -
+
MS 17.07 - Q&A
17:15 - 17:30
- Abstract
No abstract available for this presentation
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-042 - Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
09:30 - 09:30 | Presenter: Thanyanan Reungwetwattana | Author(s): S. Laohavinij, W. Lamlertthon, B. Chewaskulyong, A. Dechaphunkul, S. Detarkom, D. Muntham, N. Poovorawan, V. Srimuninnimit, V. Sriuranpong
- Abstract
Loading...